Comprehensive assessment of immune context and immunotherapy response via noninvasive imaging in gastric cancer

This study involved 2,600 patients with GC from 9 independent cohorts. We developed and validated 2 CT imaging biomarkers (lymphoid radiomics score [LRS] and myeloid radiomics score [MRS]) for evaluating the IHC-derived lymphoid and myeloid immune context respectively, and integrated them into a combined imaging biomarker [LRS/MRS: low(−) or high(+)] with 4 radiomics immune subtypes: 1 (−/−), 2 (+/−), 3 (−/+), and 4 (+/+). We further evaluated the imaging biomarkers’ predictive values on prognosis and immunotherapy response.RESULTS The developed imaging biomarkers (LRS and MRS) had a high accuracy in predicting lymphoid (AUC range: 0.765–0.773) and myeloid (AUC range: 0.736–0.750) immune context. Further, similar to the IHC-derived immune context, 2 imaging biomarkers (HR range: 0.240–0.761 for LRS; 1.301–4.012 for MRS) and the combined biomarker were independent predictors for disease-free and overall survival in the training and all validation cohorts (all P
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research